{"id":"3ea0e8b2-22b6-5258-9fed-c570a81cf381","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:lpc-day-7","predicate":"no_detected_change_in_recorded_experiment","statement":"The SA-treated LPC groups showed no significant reduction at day 7.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"3485fe1f-3e89-5901-9e7e-d0d085b840d2","mechanism_event_label":"The SA-treated LPC groups showed no significant reduction at day 7.","subject":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"object":{"id":"564b026e-004c-5c1e-840b-f9f012f5f8f2","slug":"mouse-lpc-demyelination","display_name":"Mouse LPC-model demyelination volume","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"3485fe1f-3e89-5901-9e7e-d0d085b840d2","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:lpc-day-7-event","event_type":"experimental_observation","label":"The SA-treated LPC groups showed no significant reduction at day 7.","description":"**Repair and injury prevention separated in time.** In the mouse focal lysolecithin model, shikimic acid groups did not have a smaller demyelinated region at day 7, but 100–200 mg/kg groups had less demyelination and more mature-oligodendrocyte staining at day 14. The article also reported improvement in EAE scores at 100–200 mg/kg, with a 50-mg/kg behavioral null. These model/time-dependent observations do not establish treatment of human multiple sclerosis. [Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice.](https://pubmed.ncbi.nlm.nih.gov/30684125/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"SA after LPC challenge","sequence_order":0,"notes":""},{"entity":{"id":"564b026e-004c-5c1e-840b-f9f012f5f8f2","slug":"mouse-lpc-demyelination","display_name":"Mouse LPC-model demyelination volume","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"SA after LPC challenge\", \"comparator\": \"Vehicle after LPC challenge\", \"endpoint\": \"The SA-treated LPC groups showed no significant reduction at day 7.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Mouse focal LPC demyelination; 100–200 mg/kg SA groups; day-specific histology.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Repair-time distinction, not proof of protection from initial injury or human MS efficacy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The SA-treated LPC groups showed no significant reduction at day 7.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice. | 2019 | DOI 10.1007/s12264-018-0322-7 | PMID 30684125 | https://pubmed.ncbi.nlm.nih.gov/30684125/ | https://doi.org/10.1007/s12264-018-0322-7 | https://pmc.ncbi.nlm.nih.gov/articles/PMC6527532/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 73-73; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"97ab5f68-44c6-55e4-b04e-01c0f61c1eaf","evidence_kind":"source_excerpt","locator":"Lines 73-73","start_line":73,"end_line":73,"excerpt":"**Repair and injury prevention separated in time.** In the mouse focal lysolecithin model, shikimic acid groups did not have a smaller demyelinated region at day 7, but 100–200 mg/kg groups had less demyelination and more mature-oligodendrocyte staining at day 14. The article also reported improvement in EAE scores at 100–200 mg/kg, with a 50-mg/kg behavioral null. These model/time-dependent observations do not establish treatment of human multiple sclerosis. [Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice.](https://pubmed.ncbi.nlm.nih.gov/30684125/)","model_system":"Mouse focal LPC demyelination; 100–200 mg/kg SA groups; day-specific histology.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e6ae59de-0369-5c2f-8262-57d91302671c","stable_key":"import-31b1baa4-4113-5541-b9e7-fe44a5253a07","title":"Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"95b1f9e9577661312d67f36e156d2e49326b207f296c1c0e801a5b007fd8e283","revision_id":"cd3237f1-131a-557d-84b5-7543259807b0","review_status":"unverified_draft","notes":""}}],"relations":[{"id":"7b608e17-6a9d-5e1f-8987-54b36564bd9e","relation_type":"limits_scope_of","notes":"Early injury and later repair observations differ in time; not a contradictory source.","source_claim_id":"3ea0e8b2-22b6-5258-9fed-c570a81cf381","source_claim_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:lpc-day-7","source_statement":"The SA-treated LPC groups showed no significant reduction at day 7.","target_claim_id":"bb4bc7cc-1bbd-590c-98ed-e1d83624eed9","target_claim_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:lpc-day-14","target_statement":"The SA-treated LPC groups showed less demyelination at day 14."}],"conflicts":[],"corrections":[],"research":null}